AIM AND OBJECTIVE

V. AIM AND OBJECTIVE

Drugs that have narrow absorption window in upper part of GI tract i.e. stomach and small intestine after leaving upper part of GI tract reaches to non-absorbing distal regiment, resulting lesser bioavailability.

Ketorolac Tromethamine (KT) / Aceclofenac for intranasal systemic delivery will develop with the aim to avoid gastro-intestinal complications, to improve patient compliance, to use as an alternative therapy to conventional dosage forms, to achieve controlled blood level profiles, and to obtain improved therapeutic efficacy in the treatment of postoperative pain and migraine.

Chitosan is used in cosmetics and is under investigation for use in a number of pharmaceutical formulations. The suitability and performance of Chitosan as a component of pharmaceutical formulations for drug delivery applications has been investigated in numerous studies. These include controlled drug delivery applications, use as a component of mucoadhesive dosage forms, rapid release dosage forms, improved peptide delivery, colonic drug delivery systems, and use for gene delivery. Chitosan has been processed into several pharmaceutical forms including gels, films, beads, microspheres, tablets, and coatings for liposomes.